Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SP059
Inactive Poliovirus Vaccine · 1 trial · 2 indications
Anti-Polio 1, 2 and 3 antibody titers will be determined by the Seroneutralization assay.
| Arm | Type | Description |
|---|---|---|
| Study Group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Inactive Poliovirus Vaccine | BIOLOGICAL | 0.5 mL, Subcutaneous |
Inclusion Criteria: * Aged 3 to 68 months inclusive (recommended 3 to 8 months) on the day of inclusion * Informed consent form signed by the parent(s) or other legal representative * Able to attend all scheduled visits and to comply with all trial procedures Exclusion Criteria: * Fever ≥ 37.5°C (a...
Inactive Poliovirus Vaccine is used for the prevention of poliomyelitis, commonly known as polio. It is a vaccine developed by Sanofi for protection against poliovirus infection. The vaccine is intended for use in infants, with clinical study enrollment beginning at 3 months of age.
Inactive Poliovirus Vaccine is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor of the clinical development program for this vaccine candidate.
Inactive Poliovirus Vaccine is in Phase 3 clinical development. The Phase 3 study has been completed. The vaccine is investigational and is not approved for commercial use.
Inactive Poliovirus Vaccine has been evaluated in one completed Phase 3 trial, NCT01389687, titled "Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan." The trial enrolled 74 infants in Japan and studied a three-dose primary and booster vaccination regimen.
Inactive Poliovirus Vaccine is administered subcutaneously. The Phase 3 trial NCT01389687 evaluated a three-dose primary vaccination series followed by a booster dose in infants in Japan.